IAVI and Moderna partnered to tackle broad global health priorities using mRNA for vaccines and antibodies
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
On Mar. 31, 2022, researchers in Brazil reported that a study of COVID-19 patients at 12 clinics that…
On Mar. 31, 2022, Novavax announced submission of its request to expand the conditional marketing authorization (CMA) of…
On Mar. 31, 2022, the National Institutes of Health (NIH) and Moderna announced a phase 2 clinical trial…
On Mar. 30, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service confirmed the…
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
On Mar. 21, 2022, Moderna announced announced a supply agreement with the Swiss Federal Government for seven million…
On Mar. 18, 2002, Johnson & Johnson announced an agreement to acquire all of the assets of Tibotec-Virco…
On Mar. 18, 2022, the World Health Organization (WHO) announced that Malawi had launched the first round of…
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of ProteaseInhibition…
On Mar. 7, 2022, Moderna announced that with the assistance of the U.S. Government, it had entered into…
On Mar. 2, 2022, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) confirmed the…
On Mar. 2, 2022, the World Organization for Animal Health confirmed a bald eagle found dead in British…
On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
On Feb. 23, 2022, Novavax announced the first doses of Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) had begun shipping…
On Feb. 22, 2022, Moderna announced a distribution service agreement with Adium Pharma, a leading private Latin American…
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
On Feb. 14, 2022, Novavax announced that the Singapore Health Sciences Authority (HSA) had issued interim authorization for…
On Feb. 14, 2022, Novavax announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional…